Credit: Make Medicines Affordable; ITPCThis new community report covers both the most recently approved HIV medicines and the upcoming compounds in the most advanced stages of research.
This is both an impressive review of safety and efficacy studies and also covers the key practical challenges that determine whether these drugs will benefit the majority of people living with HIV globally in low- and middle-income countries (LMICs), including drug pricing and patents.
The report, published by Make Medicines Affordable and ITPC, is easy to read and includes a brief history of the development of ART from the first NRTIs (nukes) to the latest injectable combinations.
This sets the newest HIV drugs and upcoming compounds in the context of continued developments and investment to better future drugs.
Know your history and your future – essential reading.
Reference
Make Medicines Affordable and ITPC. HIV community resource. (February 2024)
https://makemedicinesaffordable.org/wp-content/uploads/2024/03/HIV_RESOURCE.pdf
By Simon Collins, HIV i-Base
Source : HIV i-Base
Related HIV and Co-Infections News
-
[Press release] ViiV Healthcare aims to close treatment gaps for children living with HIV with paediatric Dovato marketing applications to the EMA and FDA
-
Infectious Disease Advisor: Dolutegravir plus lamivudine maintains HIV-1 suppression without HBV reactivation
-
[CROI 2026] HIV i-Base: Nine comprehensive free reviews in Topics in Antiviral Medicine
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.